Login / Register Order My Items
Contact Us
800.227.0627
Contact Us Quote Order Login / Register
dendrimer engineering • oligo conjugation chemistry • discovery to preclinical

PAMAM Dendrimer–Oligonucleotide Conjugation

CDMO-ready PAMAM dendrimer–oligonucleotide conjugation for siRNA, ASO, PNA, and PMO programs — supporting covalent PAMAM–oligo conjugates and dendriplex delivery systems with generation selection (G1–G7+), site control, cleavable linker options, purification, and CMC-aligned analytics from feasibility through scale-up.

Talk to a Scientist View Architectures
Covalent conjugates or dendriplex Generations G1–G7+ Handles: NH2 / SH / Azide / DBCO Stable or cleavable linkers HPLC/UPLC • SEC/GPC • LC-MS (where applicable)
Talk to a chemist Request a quote
Overview Architectures Generation Chemistry Analytics Reading FAQ Related Contact

Overview

PAMAM (polyamidoamine) dendrimers are monodisperse, generation-defined macromolecules with multivalent surface functionality. Their branched architecture enables high-density oligonucleotide attachment (covalent conjugates) or electrostatic complexation (dendriplex systems), supporting delivery and intracellular release designs for therapeutic nucleic acids.

As an oligonucleotide CDMO, we integrate dendrimer generation selection, end-group functionalization, conjugation chemistry, purification, and analytical characterization to reduce development risk and accelerate preclinical readiness for siRNA, ASO/SSO, PNA, and PMO programs.

Typical workflows begin with feasibility builds (mg scale) to establish architecture and CQAs, followed by optimization of shielding (e.g., partial PEGylation), linker stability (stable vs cleavable), and formulation parameters (N/P, media stability) for scale-up.

Quick facts

The best PAMAM architecture is the smallest generation and minimal surface charge needed to reach your delivery and release goal.

G1–G7+

Generation range

Covalent / Dendriplex

Two build modes

NHS / Mal / SPAAC
Top chemistries
N/P • Zeta • Size
Key formulation CQAs
PAMAM Dendrimer–Oligonucleotide Conjugation Architecture
PAMAM dendrimer–oligonucleotide conjugation architecture showing site-specific covalent conjugates, dendriplex formats, generation selection (G1–G7+), shielding options, and analytical characterization
Schematic overview of covalent PAMAM–oligonucleotide conjugates and dendriplex architectures, including generation selection (G1–G7+), surface functionalization, shielding options, and CMC-aligned analytical characterization.
DesignStoichiometry
Defined loading (covalent)

Control oligo:dendrimer ratio and attachment site using orthogonal handles for reproducible, characterizable constructs.

DeliveryTunable
Dendriplex tuning

Screen N/P ratio, shielding, and buffer systems to balance uptake, stability, unpacking, and tolerability.

CMCAnalytics
CMC-aligned CQAs

Define conjugation completeness, residual reagents, size/zeta, stability, and release to support scalable execution.

PAMAM–Oligonucleotide Architectures

CovalentDefined
1) Site-specific PAMAM–oligo conjugates

Covalent attachment provides defined stoichiometry and improved batch-to-batch reproducibility for downstream analytics and scale-up.

Best when you need a fixed, characterizable construct.
ElectrostaticDendriplex
2) Dendriplex delivery systems

Electrostatic complexation is tuned through N/P ratio, ionic strength, shielding, and serum stability to balance uptake and release.

Best for fast screening and formulation-led optimization.
ShieldedTargeting
3) Surface-modified PAMAM

Partial PEGylation and ligand installation can reduce surface charge density and tune biodistribution while maintaining multivalency.

Best to improve biocompatibility and control interactions.
Design decision shortcut
If you need defined stoichiometry and reproducible analytics → choose covalent conjugates.
If you need rapid screenability and formulation control → choose dendriplex and tune N/P + shielding.
If surface charge limits tolerability → add partial shielding (e.g., PEG) and re-optimize size/zeta.

PAMAM Generation Selection (G1–G7+)

PAMAM generation influences surface group density, loading capacity, buffering behavior, and interaction strength. We commonly start with G4–G5 for screening, then adjust generation and shielding to meet the desired balance of delivery and biocompatibility.

Generation Typical properties Where it fits
G1–G3 Lower multivalency; often lower interaction strength Low-valency conjugates; when minimizing surface charge is a priority
G4–G5 Workhorse range; useful buffering and multivalency Common starting point for siRNA/ASO delivery screening and covalent builds
G6–G7+ High surface density; higher loading; stronger interactions High-loading designs; typically paired with shielding to manage tolerability

Conjugation Chemistry & Linker Engineering

Chemistry selection is driven by the installed oligo handle, PAMAM surface functionality, buffer compatibility, and the intended stability profile (stable vs cleavable). We design coupling workflows to minimize side reactions and streamline purification.

AmineNHS
NHS–amine coupling

Activated esters form stable amide linkages with PAMAM surface amines; avoid competing nucleophiles during coupling.

Best for straightforward covalent attachment.
ThiolMaleimide
Maleimide–thiol coupling

Site-specific thioether formation using 5′/3′ thiolated oligos; control pH and protect thiols from oxidation.

Best for controlled site attachment.
ClickSPAAC
SPAAC (Azide–DBCO/BCN)

Copper-free click coupling for sensitive payloads; consider solubility of hydrophobic click handles.

Best for bioorthogonal modular builds.
Cleavable linker options
When intracellular release is desired, incorporate cleavable linkers (e.g., disulfide/redox-cleavable designs) between PAMAM and the oligo. Linker choice should align with stability windows, storage/handling, and the expected intracellular trigger environment.

Analytical Characterization (CQA Framework)

IdentityPurity
Covalent conjugates

Loading ratio, residual reagents, SEC/GPC profile, HPLC/UPLC purity, and LC-MS where applicable.

FormulationDelivery
Dendriplex systems

N/P ratio, size/PDI, zeta potential, stability in relevant media, and release/functional readouts.

StabilityRelease
Stability profiling

Storage stability and linker integrity; evaluate unpacking/release and activity retention over time.

Request a technical discussion →

FAQ

More FAQ'sAll FAQ's

Talk to a Scientist

Share your payload (siRNA/ASO/PNA/PMO), preferred format (covalent vs dendriplex), target generation, handle placement (5′/3′/internal), linker preference (stable vs cleavable), and desired scale. We will recommend architecture, coupling chemistry, purification strategy, and analytics package.

Confidential technical consult Rapid feasibility builds CMC-aligned analytics
What to include in your request
  • Oligo modality + sequence length (and strand for siRNA)
  • PAMAM generation and surface type (amine/carboxyl/hydroxyl if known)
  • Conjugation handle (NH2/SH/Azide/DBCO) and desired site (5′/3′/internal)
  • Format preference (covalent vs dendriplex) + target N/P range (if dendriplex)
  • Target quantity, timeline, and any in vitro/in vivo constraints
Request a Quote Contact

Recommended Reading

Peer‑reviewed references on PAMAM dendrimer generation effects, dendrimer–oligonucleotide complexation (polyplex / dendriplex), shielding/targeting, intracellular trafficking, and practical screening workflows.

Foundational PAMAM–oligonucleotide delivery studies
  1. Pharmaceutical Research — “PAMAM Dendrimers as Delivery Agents for Antisense Oligonucleotides.” DOI: 10.1023/A:1018926605871.
  2. Nucleic Acids Research — “Enhanced delivery of antisense oligonucleotides with fluorophore‑conjugated PAMAM dendrimers.” DOI: 10.1093/nar/28.21.4225.
Reviews and practical methods
  1. Pharmaceutics (2025) — “From Structure to Function: The Promise of PAMAM Dendrimers in Biomedical Applications.” DOI: 10.3390/pharmaceutics17070927.
  2. Review — “PAMAM dendrimers as efficient drug and gene delivery nanosystems…” Link: ScienceDirect.
  3. Methods in Molecular Biology — “PAMAM Dendrimers as a Delivery System for Small Interfering RNA.” DOI: 10.1007/978-1-0716-0290-4_5.
How to use this list (fast)
Use the Pharmaceutical Research and NAR papers to anchor mechanism and key variables (generation, charge ratio/N:P). Use the Pharmaceutics review to frame surface modification and toxicity mitigation. Use the Methods chapter for practical workflows (complex prep, screening, and readouts).

Why Choose Bio-Synthesis

Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.

Greetings Researchers,

Please be advised that any information, guidelines, writeups, and oral/video/graphic content on our website are intended solely as general guidelines.
It is the researcher's sole responsibility to conduct thorough research on the designs of the products intended for their experiments before submitting
their designs to Biosynthesis for review of production feasibility.
Thank you for your understanding.

Quick Links